For research use only. Not for therapeutic Use.
APX2039 is an orally active and potent inhibitor of the fungal Gwt1 enzyme. APX2039 has extremely potent anticryptococcal activity against C. neoformans and C. gattii. APX2039 blocks the localization of GPI (glycosylphosphatidyl inositol)-anchored cell wall mannoproteins. APX2039 can be used for Cryptococcal meningitis (CM) research[1][2].
| Catalog Number | I043525 |
| CAS Number | 2342606-49-7 |
| Synonyms | 3-[3-[[4-(6-fluoropyridin-2-yl)oxyphenyl]methyl]-1,2-oxazol-5-yl]pyridin-2-amine |
| Molecular Formula | C20H15FN4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H15FN4O2/c21-18-4-1-5-19(24-18)26-15-8-6-13(7-9-15)11-14-12-17(27-25-14)16-3-2-10-23-20(16)22/h1-10,12H,11H2,(H2,22,23) |
| InChIKey | HSPXTNVHQPVEGF-UHFFFAOYSA-N |
| SMILES | C1=CC(=NC(=C1)F)OC2=CC=C(C=C2)CC3=NOC(=C3)C4=C(N=CC=C4)N |
| Reference | [1]. Karen J Shaw, et al. 168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis. Open Forum Infect Dis. 2020 Dec 31. [2]. Yu CH, et al. Gene Expression of Diverse Cryptococcus Isolates during Infection of the Human Central Nervous System. mBio. 2021 Dec 21;12(6):e0231321. |
